The influence of finasteride on the development of prostate cancer

New England Journal of Medicine

Volumn 349, Issue 3, 2003, Pages 215-224

  Thompson, Ian M ^a   Goodman, Phyllis J ^b   Tangen, Catherine M ^b   Lucia, M Scott ^c   Miller, Gary J ^c   Ford, Leslie G ^d   Lieber, Michael M ^e   Cespedes, R Duane ^f   Atkins, James N ^g   Lippman, Scott M ^h   Carlin, Susie M ^b   Ryan, Anne ^d   Szczepanek, Connie M ⁱ   Crowley, John J ^b   Coltman Jr , Charles A ^j  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SW Oncol Group Statistical Center   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

^f USAF   (United States)

^g Southeastern Medical Oncology Center   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^j Southwest Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; STEROID 5ALPHA REDUCTASE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; URINARY DYSFUNCTION; AGED; BIOPSY; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0037812658     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030660     Document Type: Article

References (29)

1. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35.
2. Ross RK, Bernstein L, Lobo RA, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-9.
3. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-3. [Erratum, Proc Natl Acad Sci U S A 1997;94:8272.]
4. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57, 1564.
5. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52:195-202.
6. Feigl P, Blumenstein B, Thompson I, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995;16:150-63.
7. Pauler DK, Gower KB, Goodman PJ, Crowley JJ, Thompson IM. Biomarker-based methods for determining noncompliance in a prevention trial. Control Clin Trials 2002;23:675-85.
8. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
9. Cancer facts & figures, 2003. Atlanta: American Cancer Society, 2003.
10. Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology 1997;49:55-9.
11. Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA. Influence of prostate volume in the detection of prostate cancer. Urology 2003;61:167-71.
12. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
13. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.
14. Epstein JI. Pathology of prostatic neoplasia. In: Walsh PC, ed. Campbell's urology. 8th ed. Vol. 4. Philadelphia: Saunders, 2002:3025-37.
15. Smith DM, Murphy WM. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer 1994;73:1472-7.
16. Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? Urology 1999;53:696-700.
17. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996;14:Suppl 2:22-31.
18. Bostwick DG. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anat Pathol 1998;3:1-16.
19. Ishikawa S, Soloway MS, Van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141:1139-42.
20. Schatzl G, Madersbacher S, Haitel A, et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003;169:1312-5.
21. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-4.
22. Krumholtz JS, Carvalhal GF, Kamos CG, et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002;60:469-74.
23. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002;62:5119-25.
24. Gescher AJ, Sharma RA, Steward WP. Cancer prevention and delay are as important as cure. Lancet Oncol 2003;4:72-3.
25. Lippman SM, Hong WK. Cancer prevention by delay: commentary re: J.A. O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res, 8:314-346, 2002. Clin Cancer Res 2002;8:305-13.
26. Lippman SM, Hong WK. Cancer prevention by delay: commentary re: J.A. O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res, 8:314-346, 2002. Clin Cancer Res 2002;8:305-13.
27. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
28. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
29. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.